Hepatocellular carcinoma medical therapy: Difference between revisions
Jump to navigation
Jump to search
mNo edit summary |
|||
| Line 16: | Line 16: | ||
MRI is the best imaging method to detect the presence of a tumor capsule. | MRI is the best imaging method to detect the presence of a tumor capsule. | ||
== | ==Medical Therapy== | ||
* | ====Percutaneous ethanol injection==== | ||
*Percutaneous ethanol injection (PEI) well tolerated, high RR in small (< 3 cm) solitary tumors; as of 2005, no randomized trial comparing resection to percutaneous treatments; recurrence rates similar to those for postresection. | |||
*[[ | *Combined PEI and [[TACE]] can be used for tumors larger than 4 cm in diameter, although some Italian groups have had success with larger tumours using TACE alone. | ||
* [[ | ====Transcatheter arterial chemoembolization (TACE)==== | ||
*[[Transcatheter arterial chemoembolization]] (TACE) is usually performed in the treatment of large tumors (larger than 3 cm and less than 4 cm in diameter), most frequently by intraarterially injecting an infusion of antineoplastic agents mixed with iodized oil (such as Lipiodol). As of 2005, multiple trials show objective tumor responses and slowed tumor progression but questionable survival benefit compared to supportive care; greatest benefit seen in patients with preserved liver function, absence of vascular invasion, and smallest tumors. | |||
* | *Combined PEI and [[TACE]] can be used for tumors larger than 4 cm in diameter, although some Italian groups have had success with larger tumours using TACE alone. | ||
====Sealed source radiotherapy==== | |||
[[Sealed source radiotherapy]] can be used to destroy the tumor from within (thus minimizing exposure to healthy tissue). [[TheraSphere]] is an FDA approved treatment which has been shown in clinical trials to increase survival rate of low-risk patients. This method uses a catheter (inserted by a [[radiologist]]) to deposit radioactive particles to the area of interest. | |||
====Radiofrequency ablation (RFA)==== | |||
[[Radiofrequency ablation]] (RFA) uses high frequency radio-waves to ablate the tumour. | |||
====Intra-arterial iodine-131–lipiodol administration==== | |||
Intra-arterial iodine-131–lipiodol administration Efficacy demonstrated in unresectable patients, those with portal vein [[thrombus]]. This treatment is also used as adjuvant therapy in resected patients (Lau at et, 1999). It is believed to raise the 3-year survival rate from 46 to 86%. This adjuvant therapy is in phase III clinical trials in Singapore and is available as a standard medical treatment to qualified patients in Hong Kong. | |||
====High intensity focused ultrasound (HIFU)==== | |||
[[High intensity focused ultrasound]] (HIFU) (not to be confused with normal [[diagnostic ultrasound]]) is a new technique which uses much more powerful ultrasound to treat the tumour. Still at a very experimental stage. Most of the work has been done in China. Some early work is being done in Oxford and London in the UK. | |||
====Hormonal therapy==== | |||
[[Hormonal therapy]] Antiestrogen therapy with tamoxifen studied in several trials, mixed results across studies, but generally considered ineffective Octreotide (somatostatin analogue) showed 13-month MS v 4-month MS in untreated patients in a small randomized study; results not reproduced. | |||
* [[Interventional radiology]] | ====Chemotherapy==== | ||
*'''[[Chemotherapy adjuvant]]:''' No randomized trials showing benefit of neoadjuvant or adjuvant systemic therapy in HCC; single trial showed decrease in new tumors in patients receiving oral synthetic retinoid for 12 months after [[resection]]/[[ablation]]; results not reproduced. Clinical trials have varying results.<ref>[http://www.asco.org/ac/1,1003,_12-002626-00_18-0034-00_19-0027,00.asp] American Society of Clinical Oncology, 2005 Annual Meeting, Abstracts on Hepatobiliary Cancer</ref> | |||
*'''[[Palliative]]:''' Regimens that included [[doxorubicin]], [[cisplatin]], [[fluorouracil]], [[interferon]], [[epirubicin]], or [[taxol]], as single agents or in combination, have not shown any survival benefit (RR, 0%-25%); a few isolated major responses allowed patients to undergo partial hepatectomy; no published results from any randomized trial of systemic chemotherapy. | |||
====[[Interventional radiology]]==== | |||
''Abbreviations: HCC, hepatocellular carcinoma; TACE, transarterial embolization/chemoembolization; PFS, progression-free survival; PS, performance status; HBV, [[hepatitis B]] virus; PEI, percutaneous ethanol injection; RR, response rate; MS, median survival.'' | ''Abbreviations: HCC, hepatocellular carcinoma; TACE, transarterial embolization/chemoembolization; PFS, progression-free survival; PS, performance status; HBV, [[hepatitis B]] virus; PEI, percutaneous ethanol injection; RR, response rate; MS, median survival.'' | ||
| Line 43: | Line 54: | ||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} | ||
[[Category:Disease]] | |||
[[Category:Types of cancer]] | |||
[[Category:Gastroenterology]] | |||
[[Category:Hepatology]] | |||
[[Category:Oncology]] | |||
{{WikiDoc Help Menu}} | |||
{{WikiDoc Sources}} | |||
Revision as of 01:58, 19 January 2012
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [2]
|
Hepatocellular carcinoma Microchapters |
|
Differentiating Hepatocellular carcinoma from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Hepatocellular carcinoma medical therapy On the Web |
|
American Roentgen Ray Society Images of Hepatocellular carcinoma medical therapy |
|
Risk calculators and risk factors for Hepatocellular carcinoma medical therapy |
Overview
Important features that guide treatment include: -
- size
- spread (stage)
- involvement of liver vessels
- presence of a tumor capsule
- presence of extrahepatic metastases
- presence of daughter nodules
- vascularity of the tumor
MRI is the best imaging method to detect the presence of a tumor capsule.
Medical Therapy
Percutaneous ethanol injection
- Percutaneous ethanol injection (PEI) well tolerated, high RR in small (< 3 cm) solitary tumors; as of 2005, no randomized trial comparing resection to percutaneous treatments; recurrence rates similar to those for postresection.
- Combined PEI and TACE can be used for tumors larger than 4 cm in diameter, although some Italian groups have had success with larger tumours using TACE alone.
Transcatheter arterial chemoembolization (TACE)
- Transcatheter arterial chemoembolization (TACE) is usually performed in the treatment of large tumors (larger than 3 cm and less than 4 cm in diameter), most frequently by intraarterially injecting an infusion of antineoplastic agents mixed with iodized oil (such as Lipiodol). As of 2005, multiple trials show objective tumor responses and slowed tumor progression but questionable survival benefit compared to supportive care; greatest benefit seen in patients with preserved liver function, absence of vascular invasion, and smallest tumors.
- Combined PEI and TACE can be used for tumors larger than 4 cm in diameter, although some Italian groups have had success with larger tumours using TACE alone.
Sealed source radiotherapy
Sealed source radiotherapy can be used to destroy the tumor from within (thus minimizing exposure to healthy tissue). TheraSphere is an FDA approved treatment which has been shown in clinical trials to increase survival rate of low-risk patients. This method uses a catheter (inserted by a radiologist) to deposit radioactive particles to the area of interest.
Radiofrequency ablation (RFA)
Radiofrequency ablation (RFA) uses high frequency radio-waves to ablate the tumour.
Intra-arterial iodine-131–lipiodol administration
Intra-arterial iodine-131–lipiodol administration Efficacy demonstrated in unresectable patients, those with portal vein thrombus. This treatment is also used as adjuvant therapy in resected patients (Lau at et, 1999). It is believed to raise the 3-year survival rate from 46 to 86%. This adjuvant therapy is in phase III clinical trials in Singapore and is available as a standard medical treatment to qualified patients in Hong Kong.
High intensity focused ultrasound (HIFU)
High intensity focused ultrasound (HIFU) (not to be confused with normal diagnostic ultrasound) is a new technique which uses much more powerful ultrasound to treat the tumour. Still at a very experimental stage. Most of the work has been done in China. Some early work is being done in Oxford and London in the UK.
Hormonal therapy
Hormonal therapy Antiestrogen therapy with tamoxifen studied in several trials, mixed results across studies, but generally considered ineffective Octreotide (somatostatin analogue) showed 13-month MS v 4-month MS in untreated patients in a small randomized study; results not reproduced.
Chemotherapy
- Chemotherapy adjuvant: No randomized trials showing benefit of neoadjuvant or adjuvant systemic therapy in HCC; single trial showed decrease in new tumors in patients receiving oral synthetic retinoid for 12 months after resection/ablation; results not reproduced. Clinical trials have varying results.[1]
- Palliative: Regimens that included doxorubicin, cisplatin, fluorouracil, interferon, epirubicin, or taxol, as single agents or in combination, have not shown any survival benefit (RR, 0%-25%); a few isolated major responses allowed patients to undergo partial hepatectomy; no published results from any randomized trial of systemic chemotherapy.
Interventional radiology
Abbreviations: HCC, hepatocellular carcinoma; TACE, transarterial embolization/chemoembolization; PFS, progression-free survival; PS, performance status; HBV, hepatitis B virus; PEI, percutaneous ethanol injection; RR, response rate; MS, median survival.